Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment

被引:1
|
作者
Schulz, G. B. [1 ]
Stief, C. G. [1 ]
Schlenker, B. [1 ]
机构
[1] Klinikum Ludwig Maximilians Univ LMU Munchen, Urol Klin & Poliklin, Campus Grosshadern,Marchioninistr 15, D-81377 Munich, Germany
来源
UROLOGE | 2019年 / 58卷 / 09期
关键词
Urinary bladder neoplasms; Tumor surveillance; Urothelial carcinoma; Tumor recurrence; Urine cytology; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; URETHRAL RECURRENCE; TRACT RECURRENCE; RISK-FACTORS; REMNANT UROTHELIUM; TUMOR RECURRENCE; OUTCOMES; DIVERSION; SURVIVAL;
D O I
10.1007/s00120-019-1012-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Follow-up care of patients with muscle-invasive bladder cancer is subdivided into oncological and functional surveillance. More than 80% of local relapses and distant metastases occur within the first 2 years. Recurrences in the remnant urothelium also occur several years after radical cystectomy. Urinary cytology and a computed tomography (CT) scan of the abdomen and thorax including a urography phase are the standard diagnostics for tumor follow-up. There is no clear evidence for a survival benefit for the detection of asymptomatic vs. symptomatic recurrences. After partial cystectomy or trimodal treatment, there is no established follow-up schedule; however, the relatively high incidence of intravesical recurrences should be considered as there are curative treatment approaches including salvage cystectomy. Functional surveillance, which should be carried out lifelong, encompasses prevention and diagnostics of metabolic complications, urethral/ureteral strictures, problems with the urinary stoma, urinary incontinence, sexual dysfunction and urinary tract infections.
引用
收藏
页码:1093 / 1106
页数:14
相关论文
共 50 条
  • [31] Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
    de Ruiter, Ben-Max
    van Hattum, Jons W.
    Lipman, Djoeri
    de Reijke, Theo M.
    van Moorselaar, R. Jeroen A.
    van Gennep, Erik J.
    Piet, A. H. Maartje
    Donker, Mila
    van der Hulle, Tom
    Voortman, Jens
    Oddens, Jorg R.
    Hulshof, Maarten C. C. M.
    Bins, Adriaan D.
    EUROPEAN UROLOGY, 2022, 82 (05) : 518 - 526
  • [32] Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
    Hermans, Tom J. N.
    Voskuilen, Charlotte S.
    van der Heijden, Michiel S.
    Schmitz-Draeger, Bernd J.
    Kassouf, Wassim
    Seiler, Roland
    Kamat, Ashish M.
    Grivas, Petros
    Kiltie, Anne E.
    Black, Peter C.
    van Rhijn, Bas W. G.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (09) : 413 - 422
  • [33] Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer
    Vetterlein, Malte W.
    Seisen, Thomas
    Leow, Jeffrey J.
    Preston, Mark A.
    Sun, Maxine
    Friedlander, David F.
    Meyer, Christian P.
    Chun, Felix K. -H.
    Lipsitz, Stuart R.
    Menon, Mani
    Kibel, Adam S.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Quoc-Dien Trinh
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E129 - E139
  • [34] Canadian Urological Association guideline: Muscle-invasive bladder cancer
    Kulkarni, Girish S.
    Black, Peter C.
    Sridhar, Srikala S.
    Kapoor, Anil
    Zlotta, Alexandre R.
    Shayegan, Bobby
    Rendon, Ricardo A.
    Chung, Peter
    van der Kwast, Theodorus
    Alimohamed, Nimira
    Fradet, Yves
    Kassouf, Wassim
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (08): : 230 - 238
  • [35] Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations
    Hensley, Patrick J.
    Panebianco, Valeria
    Pietzak, Eugene
    Kutikov, Alexander
    Vikram, Raghu
    Galsky, Matthew D.
    Shariat, Shahrokh F.
    Roupret, Morgan
    Kamat, Ashish M.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (04): : 403 - 411
  • [36] Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: a meta-analysis of 9498 patients
    Li, Xinyuan
    Wang, Wuwan
    Zhu, Gongmin
    He, Weiyang
    Gou, Xin
    ONCOTARGET, 2018, 9 (02) : 2782 - 2796
  • [37] Treatment delays for muscle-invasive bladder cancer
    Masic, Selma
    Smaldone, Marc C.
    CANCER, 2019, 125 (12) : 1973 - 1975
  • [38] Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium
    Mir, Maria Carmen
    Marchioni, Michele
    Zargar, Homi
    Zargar-Shoshtari, K.
    Fairey, A. S.
    Mertens, Laura S.
    Dinney, C. P.
    Krabbe, L. M.
    Cookson, M. S.
    Jacobsen, N. E.
    Griffin, J.
    Montgomery, J. S.
    Vasdev, N.
    Yu, E. Y.
    Xylinas, E.
    McGrath, J. S.
    Kassouf, W.
    Dall'Era, M. A.
    Sridhar, S. S.
    Aning, J.
    Shariat, S. F.
    Wright, J. L.
    Thorpe, A. C.
    Morgan, T. M.
    Holzbeierlein, J. M.
    Bivalacqua, T. J.
    North, S.
    Barocas, D. A.
    Lotan, Y.
    Grivas, P.
    Stephenson, A. J.
    Shah, J. B.
    van Rhijn, B. W.
    Spiess, P. E.
    Daneshmand, D.
    Black, P. C.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (06): : 1347 - 1354
  • [39] Chemotherapy for Muscle-Invasive Bladder Cancer
    Trenta, Patrizia
    Calabro, Fabio
    Cerbone, Linda
    Sternberg, Cora N.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (01) : 1 - 14
  • [40] Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
    Youssef, Ramy F.
    Lotan, Yair
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 369 - 381